Trial Profile
Phase I/II trial of single-agent sphigosomal vincristine in patients with recurrent or refractory acute lymphoblastic leukaemia.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Dec 2012
Price :
$35
*
At a glance
- Drugs Vincristine (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Talon Therapeutics
- 05 Dec 2012 Results from this trial will be included in a pooled analysis to be presented at the American Society of Hematology Annual Meeting (ASH-2012) according to a Talon Therapeutics media release.